Comparative Pharmacology
Head-to-head clinical analysis: PEPCID RPD versus TRITEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID RPD versus TRITEC.
PEPCID RPD vs TRITEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
H2-receptor antagonist; competitively inhibits histamine at H2 receptors of gastric parietal cells, reducing basal and stimulated gastric acid secretion.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
300 mg orally twice daily for 14 days; alternative: 600 mg orally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
2-3 hours (prolonged to 4-5 hours in elderly or renal impairment, CrCl <30 mL/min)
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Renal: 60% unchanged; fecal: 35% (mainly metabolites)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist/Antimicrobial Combination